|The following video is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .|
CHICAGO – Yusuf Yazici, MD, discusses results from a phase 2, randomized trial evaluating a novel small molecule Wnt pathway inhibitor for the treatment of knee osteoarthritis (OA), presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois.
SM04690 is being investigated as a potential disease-modifying drug for knee OA.
Yazici Y, McAlindon TE, Gibofsky A, et al. Results from a 52 Week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis. Presented at: ACR/ARHP 2018 Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 935.
Disclosure: Dr Yazici is chief medical officer at Samumed.
This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.